Article info

Original research
Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab

Authors

  1. Correspondence to Dr David Kremer, Department of Neurology, Heinrich Heine University Düsseldorf, Dusseldorf, Germany; DavidMaxJoe.Kremer{at}med.uni-duesseldorf.de
View Full Text

Citation

Räuber S, Korsen M, Huntemann N, et al
Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab

Publication history

  • Received October 9, 2021
  • Accepted January 4, 2022
  • First published February 22, 2022.
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.